Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma.
Administration, Oral
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Boron Compounds
/ administration & dosage
Cyclophosphamide
/ administration & dosage
Dexamethasone
/ administration & dosage
Disease-Free Survival
Female
Glycine
/ administration & dosage
Humans
Male
Middle Aged
Multiple Myeloma
/ drug therapy
Recurrence
Survival Rate
ixazomib
proteasome inhibitor
relapsed myeloma
response
survival
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
02
07
2018
accepted:
08
10
2018
pubmed:
22
11
2018
medline:
28
12
2019
entrez:
22
11
2018
Statut:
ppublish
Résumé
There is a need for efficacious, convenient treatments with long-term tolerability for patients with relapsed/refractory multiple myeloma (RRMM). This phase 2 study evaluated the all-oral combination of ixazomib, cyclophosphamide and dexamethasone (ICd). Patients with RRMM received ixazomib 4 mg and cyclophosphamide 300 mg/m
Substances chimiques
Boron Compounds
0
ixazomib
71050168A2
Dexamethasone
7S5I7G3JQL
Cyclophosphamide
8N3DW7272P
Glycine
TE7660XO1C
Banques de données
ClinicalTrials.gov
['NCT02046070']
Types de publication
Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
536-546Informations de copyright
© 2018 British Society for Haematology and John Wiley & Sons Ltd.